dc.contributor.author
Spittel, Susanne
dc.contributor.author
Maier, André
dc.contributor.author
Kettemann, Dagmar
dc.contributor.author
Walter, Bertram
dc.contributor.author
Koch, Birgit
dc.contributor.author
Krause, Kerstin
dc.contributor.author
Norden, Jenny
dc.contributor.author
Münch, Christoph
dc.contributor.author
Meyer, Thomas
dc.date.accessioned
2022-02-11T14:07:46Z
dc.date.available
2022-02-11T14:07:46Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/33974
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-33693
dc.description.abstract
Background and purpose:
The aim of this study was to investigate utilization rates, treatment pathways and survival prognosis in patients with amyotrophic lateral sclerosis (ALS) undergoing non-invasive (NIV) and tracheostomy invasive ventilation (TIV) in a real-world setting.
Methods:
A prospective cohort study using a single-centre register of 2702 ALS patients (2007 to 2019) was conducted. Utilization of NIV/TIV and survival data were analysed in three cohorts: (i) non-NIV; (ii) NIV (NIV without subsequent TIV); and (iii) TIV (including TIV preceded by NIV).
Results:
A total of 1720 patients with available data were identified, 72.0% of whom (n = 1238) did not receive ventilation therapy. NIV was performed in 20.8% of patients (n = 358). TIV was performed in 9.5% of patients (n = 164), encompassing both primary TIV (7.2%, n = 124) and TIV with preceding NIV (2.3%, n = 40). TIV was more often utilized without previous NIV (25.7% vs. 8.3% of all ventilated patients), demonstrating that primary TIV was the prevailing pathway for invasive ventilation. The median (range) survival was significantly longer in the NIV cohort (40.8 [37.2–44.3] months) and the TIV cohort (82.1 [68.7–95.6] months) as compared to the non-NIV cohort (33.6 [31.6–35.7] months).
Conclusions:
Although NIV represents the standard of care, its utilization rate was low. TIV was mainly started without preceding NIV, suggesting that TIV may not be confined to NIV treatment escalation. However, TIV was pursued in a minority of patients who had previously undergone NIV. The survival benefit observed in the patients with NIV was equal to that reported in a controlled pivotal trial, but the prognosis with TIV is highly variable. The determinants of utilization of NIV/TIV and of survival (bulbar syndrome, availability of ventilation-related home nursing, cultural factors) warrant further investigation.
en
dc.rights.uri
https://creativecommons.org/licenses/by-nc/4.0/
dc.subject
amyotrophic lateral sclerosis
en
dc.subject
invasive ventilation
en
dc.subject
non-invasive ventilation
en
dc.subject
utilization rates
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Non‐invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: Utilization and survival rates in a cohort study over 12 years in Germany
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1111/ene.14647
dcterms.bibliographicCitation.journaltitle
European Journal of Neurology
dcterms.bibliographicCitation.number
4
dcterms.bibliographicCitation.originalpublishername
Wiley
dcterms.bibliographicCitation.pagestart
1160
dcterms.bibliographicCitation.pageend
1171
dcterms.bibliographicCitation.volume
28
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
DEAL Wiley
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
33210770
dcterms.isPartOf.issn
1351-5101
dcterms.isPartOf.eissn
1468-1331